United States - English - NLM (National Library of Medicine)

bausch health us llc - verteporfin (unii: 0x9pa28k43) (verteporfin - unii:0x9pa28k43) - verteporfin 15 mg - visudyne® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (cnv) due to age-related macular degeneration (amd), pathologic myopia or presumed ocular histoplasmosis. there is insufficient evidence to indicate visudyne for the treatment of predominantly occult subfoveal cnv. visudyne (verteporfin for injection) is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation [see adverse reactions (6)] . risk summary there are no data with the use of visudyne in pregnant women to inform a drug-associated risk. intravenous administration of verteporfin to pregnant rats during the period of organogenesis produced an increase in the incidence of anophthalmia/microphthalmia and wavy ribs at exposures approximately 40-fold the human exposure at the recommended clinical dose. verteporfin did not produce adverse fetal effect in rats or rabbits at exposures 6- to 20-fold the hu

United States - English - NLM (National Library of Medicine)

qlt ophthalmics, inc. - verteporfin (unii: 0x9pa28k43) (verteporfin - unii:0x9pa28k43) - verteporfin 15 mg - visudyne® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. there is insufficient evidence to indicate visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization. visudyne®   (verteporfin for injection) is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation.

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - verteporfin (unii: 0x9pa28k43) (verteporfin - unii:0x9pa28k43) - visudyne® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (cnv) due to age-related macular degeneration (amd), pathologic myopia or presumed ocular histoplasmosis. there is insufficient evidence to indicate visudyne for the treatment of predominantly occult subfoveal cnv. visudyne (verteporfin for injection) is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation [see adverse reactions ( 6)] . risk summary there are no data with the use of visudyne in pregnant women to inform a drug-associated risk. intravenous administration of verteporfin to pregnant rats during the period of organogenesis produced an increase in the incidence of anophthalmia/microphthalmia and wavy ribs at exposures approximately 40-fold the human exposure at the recommended clinical dose. verteporfin did not produce adverse fetal effect in rats or rabbits at exposures 6- to 20-fold the h

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - verteporfin -

European Union - English - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (amd) with predominantly classic subfoveal choroidal neovascularisation (cnv) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - verteporfin - powder for solution for infusion - 15mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - verteporfin - powder for solution for infusion - 15mg

Singapore - English - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - verteporfin - injection - 15 mg/vial - verteporfin 15 mg/vial

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - verteporfin 15mg - powder for infusion - 15 mg - active: verteporfin 15mg excipient: ascorbyl palmitate butylated hydroxytoluene dimyristoylphosphatidylcholine lactose monohydrate phosphatidylglycerols - visudyne is indicated for the treatment of patients with predominately classic or occult subfoveal choroidal neovascularisation due to age-related macular degeneration (amd), or with subfoveal choroidal neovascularisation caused by other macular diseases.

Canada - English - Health Canada

cheplapharm arzneimittel gmbh - verteporfin - powder for solution - 15mg - verteporfin 15mg - eent drugs, miscellaneous